Michigan State University Hematology and Medical Oncology

Fellowship · Grand Rapids, MI

Sponsored by Corewell Health – Grand Rapids/Michigan State University · Director Stephanie Dublis

Works by its people: 534
Authors: 23
First-author works: 103
Citations: 21,463

20112026

Topics

Bladder and Urothelial Cancer Treatments 36
Cancer Immunotherapy and Biomarkers 26
Retinoids in leukemia and cellular processes 26
Renal cell carcinoma treatment 24
Multiple Myeloma Research and Treatments 20
Pancreatic and Hepatic Oncology Research 13
Prostate Cancer Treatment and Research 11
Vitamin D Research Studies 10
Chronic Lymphocytic Leukemia Research 9
Estrogen and related hormone effects 8
Acute Myeloid Leukemia Research 7
Hemoglobinopathies and Related Disorders 7

Most cited

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Lancet (London, England) · 2023 · 424 citations · Sreenivasa Chandana
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
The New England journal of medicine · 2024 · 339 citations · Yousef Zakharia
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.
Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2023 · 319 citations · Sreenivasa Chandana
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
The Lancet. Oncology · 2021 · 369 citations · Yousef Zakharia
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.
Communications biology · 2021 · 302 citations · Yousef Zakharia
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
The Lancet. Oncology · 2022 · 154 citations · Yousef Zakharia
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 40 citations · Yousef Zakharia
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 36 citations · Sreenivasa Chandana

Topics

Bladder and Urothelial Cancer Treatments 36

Cancer Immunotherapy and Biomarkers 26

Retinoids in leukemia and cellular processes 26

Renal cell carcinoma treatment 24

Multiple Myeloma Research and Treatments 20

Pancreatic and Hepatic Oncology Research 13

Prostate Cancer Treatment and Research 11

Vitamin D Research Studies 10

Chronic Lymphocytic Leukemia Research 9

Estrogen and related hormone effects 8

Acute Myeloid Leukemia Research 7

Hemoglobinopathies and Related Disorders 7

Most cited

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.

Lancet (London, England) · 2023 · 424 citations · Sreenivasa Chandana

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

The New England journal of medicine · 2024 · 339 citations · Yousef Zakharia

Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.

Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2023 · 319 citations · Sreenivasa Chandana

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

The Lancet. Oncology · 2021 · 369 citations · Yousef Zakharia

Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.

Communications biology · 2021 · 302 citations · Yousef Zakharia

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

The Lancet. Oncology · 2022 · 154 citations · Yousef Zakharia

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 40 citations · Yousef Zakharia

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 36 citations · Sreenivasa Chandana